SOUTHWEST ONCOLOGY GROUP STUDIES

描述：堪萨斯大学参与了SWOG研究 从1973年开始。自1993年以来，首席调查员一直是Sarah博士 泰勒是一位热情而富有成效的临床研究人员。二十 临床研究人员参加芝加哥大学的SWOG研究 堪萨斯州，利用大学医学中心和附近的退伍军人管理局 医院。这个研究小组的目标是参与设计 和进行恶性疾病的多学科临床试验，以 在小组内调查这些疾病的生物学方面，以 调查生活质量、护理成本和长期问题 治疗并发症，开发远程医疗等新方法 增加患者收益和改善随访，参与癌症 预防试验，并对SWOG的全面领导作出贡献。 堪萨斯大学SWOG研究的参与者包括专家 从内科肿瘤学、血液学、外科、泌尿科、放射肿瘤学， 妇科肿瘤学和病理学。Giri博士是该中心的主席 和颈部放射治疗小组委员会，基姆勒博士是 临床前治疗工作坊和发展部联合主席 治疗委员会。堪萨斯州的调查人员已经协调了六个 多学科方案(四个第二阶段和两个第三阶段小组间 协议)。此外，堪萨斯州调查人员还协调了18名其他人 第二阶段或第三阶段方案和八项小组间研究。SWOG参与者 来自堪萨斯州，是14份手稿和5份摘要的主要作者， 30篇手稿和12篇摘要的合著者。 堪萨斯大学及其10个附属机构登记了115名患者 SWOG在1995年和1996年对91名患者进行了研究。1996年，堪萨斯州是 在SWOG中排名第17位。目前，587名患者还活着， 在SWOG研究中被跟踪，在SWOG机构中排名第十。

Description: The University of Kansas has participated in SWOG studies since 1973. The Principal Investigator since 1993 has been Dr. Sarah Taylor, an enthusiastic and productive clinical investigator. Twenty clinical investigators participate in SWOG studies at the University of Kansas, utilizing both the University Medical Center and the nearby VA Hospital. The goals of this research group are to participate in the design and conduct of multidisciplinary clinical trials in malignant diseases, to investigate biological aspects of these diseases within the group, to investigate issues of quality of life, cost of care and long-term complications of treatment, to develop new methods such as telemedicine to increase patient accrual and improve follow-up, to participate in cancer prevention trials, and to contribute to the overall leadership of the SWOG. Participants in SWOG studies at the University of Kansas include specialists from medical oncology, hematology, surgery, urology, radiation oncology, gynecological oncology, and pathology. Dr. Giri is the chair of the Head and Neck Radiation Therapy Subcommittee, and Dr. Kimler is the chair of the Pre-Clinical Therapeutics Workshop and co-chair of the Developmental Therapeutics Committee. Kansas investigators have coordinated six multidisciplinary protocols (four phase II and two phase III intergroup protocols). In addition, Kansas investigators have coordinated 18 other phase II or III protocols and eight intergroup studies. SWOG participants from Kansas were the primary authors of 14 manuscripts and 5 abstracts and co-authors of 30 manuscripts and 12 abstracts. The University of Kansas and its 10 affiliates registered 115 patients to SWOG studies in 1995 and 91 patients in 1996. In 1996, Kansas was the seventeenth leading accruer in SWOG. Currently, 587 patients are alive and being followed on SWOG studies, ranking tenth among SWOG institutions.